Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm focused on the development and commercialization of advanced biopharmaceutical products. The company leverages its proprietary technologies and a diverse product pipeline to address critical medical needs, positioning itself strategically to enhance treatment outcomes across multiple therapeutic areas. With a robust commitment to research and development, ZYBT aims to drive significant growth and deliver substantial value to its investors, while maintaining a strong emphasis on quality and innovation within the dynamic biotechnology landscape.
| Revenue (TTM) | $153.74M |
| Gross Profit (TTM) | $57.45M |
| EBITDA | $-2.21M |
| Operating Margin | -46.30% |
| Return on Equity | -6.38% |
| Return on Assets | -3.45% |
| Revenue/Share (TTM) | $3.31 |
| Book Value | $0.92 |
| Price-to-Book | 0.99 |
| Price-to-Sales (TTM) | 0.28 |
| EV/Revenue | 2.182 |
| EV/EBITDA | 17.36 |
| Quarterly Earnings Growth (YoY) | -79.60% |
| Quarterly Revenue Growth (YoY) | -34.40% |
| Shares Outstanding | $47.39M |
| Float | $4.42M |
| % Insiders | 0.00% |
| % Institutions | 3.12% |